Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. However, T-cell depletion increases the risk of graft rejection. This study examined the use of CD52 mon...
Príomhchruthaitheoirí: | Hale, G, Zhang, M, Bunjes, D, Prentice, H, Spence, D, Horowitz, M, Barrett, A, Waldmann, H |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
1998
|
Míreanna comhchosúla
Míreanna comhchosúla
-
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
de réir: Hale, G, et al.
Foilsithe / Cruthaithe: (2000) -
Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo.
de réir: Cobbold, S, et al.
Foilsithe / Cruthaithe: (1986) -
Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection.
de réir: Brewer, Y, et al.
Foilsithe / Cruthaithe: (1989) -
In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
de réir: Willemze, R, et al.
Foilsithe / Cruthaithe: (1992) -
Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia.
de réir: Treleaven, J, et al.
Foilsithe / Cruthaithe: (1996)